PharmEasy

The company has a total workforce of about 1500

Development follows shelving of IPO plans by several notable firms such as Image Marketing (owner of wearable brand Boat), Droom Technology and PharmEasy

Technology investor Prosus on Wednesday reported widening of its consolidated trading loss to USD 80 million, about Rs 654 crore, on account of investment in PayU India business during first half of the current fiscal. The Netherlands-based investor firm, however, registered a 59 per cent growth in total payments volume (TPV) at USD 28 billion, about Rs 2.29 lakh crore, in India. PayU revenue increased to USD 183 million, about Rs 1,497 crore. "Consolidated trading losses expanded to USD 80 million, as we continued to invest in growing our credit operations in India. In India, our largest payments market, TPV grew 59 per cent to USD 28 billion, and revenue increased 48 per cent to USD 183 million, following increased digitalisation in e-commerce, financial services and bill payments, and a rebound in post pandemic travel," the company said. The Prosus group's overall trading loss widened to USD 1.4 billion during the reported period from USD 2.8 billion a year ago. The revenue of

Share prices, trading activity slump amid rising uncertainty for startup listings

Financing will help Elev8 identify investment opportunities in Indian technology companies

Debt financing platform's investment amount was not revealed; it will make equity infusion later

Rising Sebi scrutiny, poor investor response during roadshows seen as reasons for withdrawal by companies

Actor facing flak for ad for AU Small Finance Bank; not new to controversy, which could affect brand value, say experts

Inflation trajectory and the actions of global central banks, especially the US Fed will be keenly watched by market participants. In this backdrop, primary markets will remain in wait and watch mode

Shares of new-age companies have dropped more than 60% amid liquidity squeeze.

API Holdings, the parent company of PharmEasy, wrote to shareholders announcing withdrawal of DRHP

Indian drug and medical services startup PharmEasy is in talks with investors to raise $200 million, but at a valuation that could be 15% or even 25% lower than last year's $5.1 billion

Falling valuations, slowing funding rounds add to woes; move aimed at conserving cash and shore up profitability

After the boom of 2021, when 44 Indian startups became unicorns, the markets are more selective and investors less enthusiastic in participating at unrealistic valuations

Oyo made preliminary filings in September aiming for an IPO in early 2022

Sebi probing IPO-bound firms on non-financial metrics, says report; the push comes after Paytm's IPO debacle

API Holdings, the parent company of PharmEasy, Adar Poonawalla-backed Wellness Forever Medicare and metal recycling firm CMR Green Technologies received Sebi's nod for IPOs

Planned smaller IPOs could have a harder time pricing shares if there is a reduced appetite for new listings

Success depends on its ability to integrate various entities across the healthcare value chain

The issue will comprise only primary share sale